In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alkermes Contract Pharma Services

Division of Alkermes PLC

Latest From Alkermes Contract Pharma Services

Recent Financings Of Private Companies, September 2012

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

BioPharmaceutical Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011

Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.

Deals Shaping the Medical Industry (06/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Start-Up Quarterly Statistics, Q4 2008

Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Elan Pharmaceutical Technologies
  • Elan Drug Technologies Inc.
  • NanoSystems
  • Elan Drug Delivery Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Alkermes PLC
  • Senior Management
  • Shane Cooke, EVP & Head
    Johannes Roebers, PhD, SVP & Head, R&D
  • Contact Info
  • Alkermes Contract Pharma Services
    Phone: 9064 95000
    Monksland, Athlone
    Co Westmeath
    Dublin, PA